Predict your next investment

HEALTHCARE | Biotechnology
biodel.com

See what CB Insights has to offer

Founded Year

2003

Stage

Acq - P2P | Acquired

Total Raised

$21M

About Biodel

Biodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called ViajectTM to treat patients with Type 1 and Type 2 diabetes. On May 17, 2007, Biodel had its initial public offering and now trades on Nasdaq under the symbol 'BIOD."

Biodel Headquarter Location

100 Saw Mill Road

Danbury, Connecticut, 06810,

United States

203-796-5000

Latest Biodel News

Enanta Pharmaceuticals to Host Conference Call on August 7 at 430 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30 2017

Jul 25, 2017

Biodel to Report Third Quarter Fiscal Year 2011 Financial Results on August 4, 2011 Conference Call and Webcast Information To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on August 7, 2017, through 11:59 p.m. ET on August 10, 2017 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 47670579. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com . About Enanta Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Enanta has also discovered novel protease inhibitors that have been developed as part of AbbVie’s hepatitis C virus (HCV) treatment regimens under a collaboration that now provides Enanta a payment stream, which it is using to fund its research and development programs. Please visit www.enanta.com for more information on Enanta’s programs and pipeline. View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005229/en/ Investor Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biodel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biodel is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Biodel Patents

Biodel has filed 14 patents.

The 3 most popular patent topics include:

  • Insecticides
  • Agricultural pest nematodes
  • Invasive plant species
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/9/2019

8/10/2021

Tylenchida, Invasive plant species, Agricultural pest nematodes, Insecticides, Plant physiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/9/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/10/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Tylenchida, Invasive plant species, Agricultural pest nematodes, Insecticides, Plant physiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.